表紙
市場調查報告書

思覺失調症治療藥市場分析與預測:各治療等級(第2代、第3代抗精神病藥)、治療(口服、注射劑)、主要市場及各市場區隔,2016年∼2022年

Schizophrenia Drugs Market Analysis, By Therapeutic Class (Second-Generation, Third-Generation Antipsychotics), By Treatment (Oral, Injectables), By Major Markets, And Segment Forecasts, 2016 - 2022

出版商 Grand View Research, Inc. 商品編碼 600802
出版日期 內容資訊 英文 103 Pages
商品交期: 2-3個工作天內
價格
Back to Top
思覺失調症治療藥市場分析與預測:各治療等級(第2代、第3代抗精神病藥)、治療(口服、注射劑)、主要市場及各市場區隔,2016年∼2022年 Schizophrenia Drugs Market Analysis, By Therapeutic Class (Second-Generation, Third-Generation Antipsychotics), By Treatment (Oral, Injectables), By Major Markets, And Segment Forecasts, 2016 - 2022
出版日期: 2017年11月03日內容資訊: 英文 103 Pages
簡介

全球思覺失調症治療藥市場,根據Grand View Research,Inc.的最新報告,預計至2022年達到79億美元。思覺失調症市場,由於尋求藥物輸送技術的改善,長期作用性注射劑(LAI)及治療的患者的增加,整體上預計成長。藥理效果快的表現,患者取得容易,有效性,及患者的服藥遵守高等有助於新藥攝取。

思覺失調症,對患者、其家族及社會全體上很大的負擔。由於心理健康,尤其是思覺失調症領域的患者和醫生的意識高漲,這些藥物深入到市場的可能性變得高。現在,第2代及第3代的抗精神病藥物大幅獲得市場佔有率。臨床試驗中的開發平台藥物打算阻斷5-羥色胺和多巴胺受體的特定亞型,有助於最小化症狀,調節多巴胺濃度,並進一步改善記憶。

本報告提供全球思覺失調症治療藥市場相關調查,市場概要和各治療等級、治療、主要市場及各市場區隔趨勢,加入此市場的主要企業的簡介等彙整資料。

目錄

第1章 調查方法

  • 資訊採購
  • 資訊或資料分析

第2章 摘要整理

第3章 疾病入門與流行病學

  • 本章概要

第4章 全球市場概要

  • 本章概要
  • 簡介與市場概要
  • 各治療等級市場
  • 市場規模與預測
  • 各藥物等級銷售業績
  • 市場佔有率分佈
  • 領導品牌間的市場趨勢
  • 專利到期分析
  • 思覺失調症市場:成長促進因素及阻礙因素
  • M&A,交易情形(2013-2017 YTD)
  • 新興市場
  • 價格設定及回本方案
  • 思覺失調症部門的SWOT分析

第5章 開發平台資訊

  • 開發平台情形

第6章 企業簡介

  • 本章概要
  • Johnson & Johnson
  • Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals
  • AstraZeneca
  • Eli Lilly
  • Alkermes
  • 大日本住友製藥
  • Pfizer
  • Vanda Pharmaceuticals
  • Allergan (Forest Labs)/ Geodon Ritcher

第7章 市場預測

  • 未來是什麼樣子
  • 勝者和敗者
  • 新興企業/新技術平台
  • 前途
目錄
Product Code: GVR-2-68038-222-8

The global schizophrenia drugs market is expected to be valued at USD 7.9 billion by 2022, as per a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Further key findings from the report suggest:

  • The global schizophrenia drugs market is segmented by therapeutic class into first, second and third-generation antipsychotics
  • Few of the prominent players operating in this industry are Johnson & Johnson, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan and Pfizer
  • Several market players are expected to work upon serving the unmet market needs, identifying new targets and consequentially develop stronger drug pipelines
  • The market share captured by generics is expected to grow by 2022, due to branded drugs losing their patent exclusivity and becoming generic
  • Regionally, among the EU5 markets, Germany captured the second position in the global schizophrenia drugs market. Japan is expected to witness the fastest growth over the forecast period
  • China and India are emerging as an opportunity for market expansion
x

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1 Chapter Summary
    • 3.1.1 Disease Primer
    • 3.1.2 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU 5)

Chapter 4 Global Market Overview

  • 4.1 Chapter Summary
  • 4.2 Introduction and Market Overview
  • 4.3 Market, by Therapeutic Class
  • 4.4 Market Size and Forecast
  • 4.5 Sales Performance, by Drug Class
  • 4.6 Market Shares Distribution
  • 4.7 Market Dynamics Among Leading Brands
  • 4.8 Patent Expiry Analysis
  • 4.9 Schizophrenia Market: Drivers and Restraints
    • 4.9.1. Drivers
    • 4.9.2. Challenges
  • 4.10. M&A, Deal Landscape (2013-2017 YTD)
    • 4.10.1. Mergers & Acquisitions
    • 4.10.2. Deals Landscape
  • 4.11. Emerging Markets
  • 4.12. Pricing and Reimbursement Scenario
  • 4.13. Schizophrenia Sector SWOT

Chapter 5 Pipeline Intelligence

  • 5.1. Pipeline Landscape
    • 5.1.1. Leading Drugs in Development
    • 5.1.2. Key R&D Trends
  • 5.2. Pipeline Landscape
    • 5.2.1. Late Stage Pipeline Drugs
    • 5.2.2. Profiles of Disruptive Drugs
    • 5.2.3. Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1. Chapter Summary -
  • 6.2. Johnson & Johnson
    • 6.2.1. Company Overview
    • 6.2.2. Current Product Portfolio
    • 6.2.3. Product Forecast Sales through 2022
    • 6.2.4. Strategic Initiatives
      • 6.2.4.1. Key Company News Flow
    • 6.2.5. SWOT
  • 6.3. Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals
    • 6.3.1. Company Overview
    • 6.3.2. Current Product Portfolio
    • 6.3.3. Product Forecast Sales through 2022
    • 6.3.4. Strategic Initiatives
      • 6.3.4.1. Key Company News Flow
    • 6.3.5. Catalysts and Event Calendar
    • 6.3.6. Pipeline Analysis and Overview
    • 6.3.7. SWOT
  • 6.4. AstraZeneca
    • 6.4.1. Company Overview
    • 6.4.2. Current Product Portfolio
    • 6.4.3. Product Forecast Sales through 2022
    • 6.4.4. Strategic Initiatives
      • 6.4.4.1. Key Company News Flow
    • 6.4.5. SWOT
  • 6.5. Eli Lilly
    • 6.5.1. Company Overview
    • 6.5.2. Current Product Portfolio
    • 6.5.3. Product Forecast Sales through 2022
    • 6.5.4. Strategic Initiatives
      • 6.5.4.1. Key Company News Flow
    • 6.5.5. SWOT
  • 6.6. Alkermes
    • 6.6.1. Company Overview
    • 6.6.2. Current Product Portfolio
    • 6.6.3. Product forecast sales through 2022
    • 6.6.4. Strategic Initiatives
      • 6.6.4.1. Key Company News Flow
    • 6.6.4. Pipeline Analysis & Overview
    • 6.6.5. SWOT
  • 6.7. Sumitomo Dainippon Pharma
    • 6.7.1. Company Overview
    • 6.7.2. Current Product Portfolio
    • 6.7.3. Product Forecast Sales through 2022
    • 6.7.4. Strategic Initiatives
      • 6.7.4.1. Key Company News Flow
    • 6.7.5. Pipeline Analysis & Overview
    • 6.7.6. Pipeline Forecast
    • 6.7.7. SWOT
  • 6.8. Pfizer
    • 6.8.1. Company Overview
    • 6.8.2. Current Product Portfolio
    • 6.8.3. Product Forecast Sales through 2022
    • 6.8.4. Strategic Initiatives
      • 6.8.4.1. Key Company News Flow
    • 6.8.5. Pipeline Analysis & Overview
    • 6.8.6. SWOT
  • 6.9. Vanda Pharmaceuticals
    • 6.9.1. Company Overview
    • 6.9.2. Current Product Portfolio
    • 6.9.3. Product Forecast Sales through 2022
    • 6.9.4. Strategic Initiatives
      • 6.9.4.1. Key Company News Flow
    • 6.9.5. SWOT
  • 6.10. Allergan (Forest Labs)/ Geodon Ritcher
    • 6.10.1. Company Overview
    • 6.10.2. Current Product Portfolio
    • 6.10.3. Product Forecast Sales through 2022
    • 6.10.4. Strategic Initiatives
      • 6.10.4.1. Key Company News Flow
    • 6.10.5. SWOT

Chapter 7 Market Outlook

  • 7.1. What the Future Holds
  • 7.2. The Winners and Losers
  • 7.3. Emerging Companies/New Technology Platforms
  • 7.4. The Road Ahead

List of Tables

  • TABLE 1 Age and Gender Specific Prevalence of Schizophrenia in the U.K.
  • TABLE 2 U.S. Patents for Current Schizophrenia Drugs
  • TABLE 3 Total and Per Patient Cost for Schizophrenia by Region
  • TABLE 4 R&D Pipeline Overview
  • TABLE 5 Late Stage Pipeline
  • TABLE 6 Pipeline Forecast
  • TABLE 7 Johnson & Johnson- Product Forecast Sales through 2022
  • TABLE 8 Bristol-Myers Squibb/ Otsuka Pharma- Product Forecast Sales through 2022
  • TABLE 9 AstraZeneca- Product Forecast Sales through 2022
  • TABLE 10 Eli Lilly- Product Forecast Sales through 2022
  • TABLE 11 Alkermes- Product Forecast Sales through 2022
  • TABLE 12 Sumitomo Dainippon- Product Forecast Sales through 2022
  • TABLE 13 Pfizer- Product Forecast Sales through 2022
  • TABLE 14 Vanda Pharma- Product Forecast Sales through 2022
  • TABLE 15 Allergan- Product Forecast Sales through 2022

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Positive Symptoms Associated with Schizophrenia
  • FIG. 8 Negative Symptoms Associated with Schizophrenia
  • FIG. 9 Cognitive Symptoms Associated with Schizophrenia
  • FIG. 10 Lifetime Risk of Schizophrenia
  • FIG. 11 Percentage of Schizophrenia Onset by Age and Gender
  • FIG. 12 Age and Gender Specific Prevalence of Schizophrenia in the U.S.
  • FIG. 13 Age and Gender Specific Incidence of Schizophrenia in the U.S.
  • FIG. 14 Age and Gender Specific Prevalence of Schizophrenia in Europe
  • FIG. 15 Incidence of Schizophrenia Based on Ethnic Group in the U.K.
  • FIG. 16 Prevalence of Schizophrenia in Japan
  • FIG. 17 Regional Market Size 2016-2022
  • FIG. 18 Market Share, by Drug Class 2016-2022
  • FIG. 19 Market Share, by Mode of Administration- Oral vs LAIs 2016-2022
  • FIG. 20 Market Shares, by Company 2016-2022
  • FIG. 21 Schizophrenia Sector SWOT
  • FIG. 22 Johnson & Johnson SWOT Analysis
  • FIG. 23 Bristol-Myers Squibb/ Otsuka Pharma SWOT Analysis
  • FIG. 24 AstraZeneca SWOT Analysis
  • FIG. 25 Eli Lilly SWOT Analysis
  • FIG. 26 Alkermes SWOT Analysis
  • FIG. 27 Sumitomo Dainippon SWOT Analysis
  • FIG. 28 Pfizer SWOT Analysis
  • FIG. 29 Vanda Pharma SWOT Analysis
  • FIG. 30 Allergan SWOT Analysis
Back to Top